BuyandBill.com · Blog

Notes from the people who run the site

What changed and why, plus short explainers on the coding and pricing questions we get asked most. Drug alerts live in the newsletter.

A diverging bar chart of the eight largest payment limit changes in the preliminary October 2026 file: zoledronic acid J3489 up 425.8 percent, pentamidine J2516 up 201.2 percent, labetalol HCl J1920 up 170.2 percent and Omnipaque 180 Q9965 up 138.3 percent on one side of a no-change line; pemetrexed J9305 down 82.3 percent, terbutaline J3105 down 64.6 percent, Ruxience Q5119 down 64.2 percent and capecitabine J8522 down 63.8 percent on the other Latest

Drug Pricing 13 min read

Q4 2026 Payment Limits: Where the Money Actually Moved

CMS has published the preliminary October 2026 Medicare Part B payment limit file. 178 codes moved at least 10 percent, and several of the largest swings are methodology changes rather than market moves. What changed, and what to check before October 1.

Read the post →
  1. Coding & Billing

    The Next Coding Crisis: Generics Chasing 505(b)(2) Drugs

    ANDA generics are now filing against 505(b)(2) products as their reference drug, and the J-code lineage is getting harder to trace. Why payers, providers, and claims systems were never designed for it.

  2. Coding & Billing

    NDC Listing Errors: 5 Common Drug Data Problems

    NDC listing errors happen when FDA, CMS, and drug pricing compendia disagree. The 5 most common types, real examples, and how to find and fix them.